Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.58 |
| ▸ | CDK2 | P24941 | 6/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.54 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.54 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.54 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.50 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5827480 | 0.90 | CTSL (0.56) | CTSLCDK2CCNA2CCNA1CACNA1B | |
| SCHEMBL5827932 | 0.86 | CTSL (0.58) | CTSLCDK2CCNA2CCNA1CACNA1B | |
| SCHEMBL5827773 | 0.84 | CDK2 (0.58) | CTSLCDK2CCNA2CCNA1CACNA1B | |
| SCHEMBL27581375 | 0.84 | CTSL (0.63) | CTSLCDK2CCNA2CCNA1CACNA1B | |
| SCHEMBL6152650 | 0.84 | CTSL (0.69) | CTSLCDK2CCNA2CCNA1CACNA1B | |
| SCHEMBL5828674 | 0.82 | CDK5 (0.69) | CDK2CCNA2CCNA1CDK5CDK5R1 | |
| SCHEMBL5827675 | 0.80 | CDK2 (0.75) | CTSLCDK2CCNA2CCNA1CACNA1B | |
| SCHEMBL5827977 | 0.79 | CDK5 (0.54) | CTSLCDK2CCNA2CCNA1CACNA1B | |
| SCHEMBL5828592 | 0.76 | CCNE2 (0.70) | CTSLCDK2CCNA2CTSBCDK5 | |
| SCHEMBL17639878 | 0.75 | PDE2A (0.58) | CTSLCDK2CCNA2CCNA1CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020035252-A1 | Purine inhibitors of cyclin dependent kinase 2 & IkBa | LUM ROBERT T (US) | 2002-03-21 | — | — | US | claimed |
| EP-1150982-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND I$g(k)-A$g(a) | CV THERAPEUTICS, INC. (US) | 2001-11-07 | — | — | EP | claimed |
| WO-2000044750-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND Iλ-A$g(a) | CV THERAPEUTICS, INC. (US) | 2000-08-03 | — | — | WO | claimed |
| US-7109330-B2 | Purine inhibitors of cyclin dependent kinase 2 and IκB-α | CV THERAPEUTICS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | LUM ROBERT T (US) | 2005-04-14 | — | — | US | disclosed |
| US-6790958-B2 | ANTIPROLIFERATIVE AGENTS; FUNGICIDES | LUM ROBERT T (US) | 2004-09-14 | — | — | US | disclosed |
| US-20020035252-A1 | Purine inhibitors of cyclin dependent kinase 2 & IkBa | LUM ROBERT T (US) | 2002-03-21 | — | — | US | disclosed |
| EP-1150982-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND I$g(k)-A$g(a) | CV THERAPEUTICS, INC. (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000044750-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND Iλ-A$g(a) | CV THERAPEUTICS, INC. (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | IKBKB, NFKB1, CDK4 | CTSL 3859/4885CDK2 5/4885CCNA2 22/4885 |
| US-20020035252-A1 | Purine inhibitors of cyclin dependent kinase 2 & IkBa | AURKB, CDKN1A, IKBKB | CTSL 2544/4885CDK2 8/4885CCNA2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.